Professional Documents
Culture Documents
Sector outlook
Thanks for your support in the
Please click here for our voting matrix.
CLSA and CL Securities Taiwan Co., Ltd. (“CLST”) do and seek to do business with companies covered in its research reports. As such,
investors should be aware that there may be conflicts of interest which could affect the objectivity of the report. Investors should consider
this report as only a single factor in making their investment decisions. For important disclosures please refer to page 19.
Prepared for - RD: Visible Alpha
CLSA India Real Estate Access Day India Property
We would like to thank Evalueserve for its help in preparing our research reports. Ashit Jain (Consumer), Akshay Chandak (Strategy and Oil & Gas), Ayush Gandhi
(Strategy), Keshub Bhat (IT) and Zen Javeri (Power, Infra and Capital Goods) provide research support services to CLSA.
Figure 2
Price hikes by a few There are early signs of prices hikes of 5-10% by a few well-reputed developers (eg
developers have been DLF, Sobha, Mahindra) in the past six months, which have been absorbed by the
absorbed by the market market, indicating strong demand, especially for reputable developers.
Figure 3
Find CLSA research on Bloomberg, Thomson Reuters, FactSet and CapitalIQ - and profit from our evalu@tor proprietary database at clsa.com
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
We assess the new acquisition strategies of developers vis-à-vis the size of their
existing land banks, their leverage and cash flow generation. We thus believe
companies such as Sunteck, Prestige Estates, Oberoi Realty and Mahindra
Lifespaces are being prudent in their acquisition strategies in terms of capital
allocation.
Figure 12
The silver lining is that occupants in the office parks have started calling their
employees back to offices. Embassy’s management highlighted that a few of its
occupants that had surrendered space earlier are having second thoughts and want
to come back.
Figure 13
New completions in 2QCY21 were recorded at 11.67msf, more than double than
those in 2QCY20. During the first wave of Covid-19, new completions took a hit
due to the unavailability of labour. The robust new completion level in 2QCY21
indicates that construction activity was not impacted significantly during the
second wave.
Figure 14
Due to a steady pipeline of assets coming online, the demand-supply gap has
momentarily widened. Vacancy levels across the top seven markets rose to nearly
16% at the end of 2QCY21, breaching the comfort zone of 13-14% for the first time
since 2017.
Figure 15
Source: JLL
Office rentals remained stable across the major office markets in India in 2QCY21.
However, landlords continue to accommodate the demands of occupants and
support closure of deals. With vacancy levels already hovering at around 16%, the
next few quarters will be critical to see if pick-up in demand can maintain market
buoyancy as planned supply enters the market.
Figure 16
More consumers are using Virtual demand index – Top eight cities
online platforms for their
property purchases or
rentals
Source: Housing.com
Figure 17 Figure 18
As the pandemic has given the market an impetus to explore online business
platforms, Housing.com’s survey suggests that a majority (60%) of the respondents
were willing to explore such platforms to both buy and rent a home. Although the
initial process of buying or renting a home may start online, 47% of respondents
were willing to close the deal after multiple site visits. However, a significant 37%
of respondents were willing to close the deal after one site visit or close it entirely
online.
Figure 19
Company section
DLF
Figure 20
SoTP Valuation
Business segment Valuation basis Stake (%) Equity value (Rs Rs per
bn) share
Residential business
- Residential projects DCF, WACC of 12% 100% 69 27.7
- Land bank 30% discount to 100% 464 187.5
market value
Figure 21
Embassy REIT
Figure 22
SoTP valuation
Project name Location EOP REIT's Enterprise EOP REIT's
stake value stake in EV
(%) (Rs bn) (Rs bn)
Embassy Manyata Bangalore 100% 188 188
Embassy Tech Village Bangalore 100% 88 88
Express Towers Mumbai 100% 19 19
Embassy 247 Mumbai 100% 16 16
FIFC Mumbai 100% 14 14
Embassy Techzone Pune 100% 36 36
Embassy Quadron Pune 100% 14 14
Embassy Qubix Pune 100% 11 11
Embassy Oxygen Noida 100% 25 25
Embassy Galaxy Noida 100% 10 10
Embassy One Bangalore 100% 5 5
Hilton at Embassy Golflinks Bangalore 100% 1 1
Embassy Energy Bellary District, 100% 13 13
Karnataka
Total (100% owned assets) 442 442
Embassy Golflinks Bangalore 50% 63 32
Total EV 506 474
Less: Net debt (100% owned assets) 100% 100 100
Less: Net debt of Embassy Golf Links 50% 3 2
Less: PV of redemption premium on zero coupon NCDs 10 10
Less: Security deposits (incl. 50% of Golf Links) 16
Total equity value (Mar-22) 346
Units O/S (m) 948
Target price (Mar-22) (Rs/ share) 365
Source: CLSA
Godrej Properties
Figure 23
SoTP valuation
Sale business (ex- Vikhroli land)
FY23 pre-sales (Rs bn) - ex Vikhroli 79 FY20 Rs59bn; Vikhroli (Mumbai)
valued separately
Assume steady state PAT margin (%) 10 Rising project stakes/JV project
share; Base fee/JV margins at 8-12%
Steady state PAT (Rs bn) 7.9
Target PAT multiple 35.0
Equity value business - ex Vikhroli (Rs bn) 277
Per share value of business ex Vikhroli (A) 1,098
Oberoi Realty
q It will look at acquiring relatively smaller land parcels (compared to its existing large
projects) to ensure faster churn of projects.
Figure 24
SoTP Valuation
Business segment Valuation basis Total value (Rs Rs per
bn) share
Residential business
- Ongoing projects DCF, WACC of 12% 79.8 219.5
- Forthcoming projects/ land DCF, WACC of 12%/ market value of 61.8 170.0
bank land
Hospitality business
- Operational projects EV/ EBITDA of 6x 1.8 4.8
- Under-construction Valued at purchase cost 5.4 14.9
projects
Phoenix Mills
Figure 25
SoTP Valuation
Business segment Valuation basis Equity value (Rs bn) Rs per share
Malls
- Operational Cap rate of 6.2-7.0% 109.2 635
- Under-construction Cap rate of 8.5% 37.0 215
Offices
- Operational Cap rate of 8.5% 7.5 43
- Under-construction Cap rate of 9.5% 0.6 3
Hospitality business
- Operational projects EV/ EBITDA of 6x 0.3 2
Prestige Estates
Figure 26
SoTP Valuation
Business segment Valuation basis Total value (Rs bn) Rs per share
Residential business
- Ongoing projects DCF, WACC of 12% 32.2 80
- Forthcoming projects DCF, WACC of 14% 29.9 75
- Land bank 50% discount to market 12.0 30
value
Hospitality business
- Operational projects EV/ EBITDA of 6x 6.3 16
- Under-construction projects No value assigned - -
Sobha
Figure 27
SoTP valuation
Business segment Valuation basis Total value (Rs bn) Rs per share
Residential business
- Ongoing projects DCF, WACC of 12% 29.7 313
- Land bank At 35% discount to market 39.2 414
value
Sunteck Realty
q It will pay an upfront FSI premium in FY22 to take advantage of 50% cut in the
premium rates by the state government, which will result in overall savings of Rs2.5bn
on premium costs and also result in improved margins.
Figure 28
NAV
(Rs bn) Area (msf) Expected net Monetization period NPV
cash flow (no. of years)
BKC projects
Signature Island 0.7 7.5 5.0 5.6
Signia Isles 0.4 1.1 2.0 1.0
Signia Pearl 0.4 3.3 3.0 2.8
Sub-total 1.5 11.9 10.0 9.4
Housing.com (Unlisted)
Research subscriptions
To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com.
You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email_alert/.
Companies mentioned
Brigade Enterprises Ltd (N-R)
DLF (DLFU IB - RS294.9 - O-PF)
Embassy REIT (EMBASSY IN - RS352.6 - BUY)
Godrej Properties (GPL IB - RS1,482.0 - SELL)
Housing.com (N-R)
Kolte Patil Developers Ltd (N-R)
Lodha International (N-R)
Macrotech (N-R)
Mahindra Lifespace (N-R)
Oberoi Realty (OBER IN - RS654.2 - BUY)
Phoenix Mills (PHNX IN - RS847.7 - BUY)
Prestige Estates (PEPL IN - RS287.5 - BUY)
Propstack (N-R)
Puravankara (N-R)
Sobha (SOBHA IS - RS517.0 - O-PF)
Sunteck Realty (SRIN IN - RS306.9 - BUY)
Analyst certification
The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our
own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will
be directly or indirectly related to the specific recommendation or views contained in this research report.
Important disclosures
The policy of CLSA, CLSA Americas, LLC ("CLSA Americas") and CL related to the specific recommendation or views contained in this
Securities Taiwan Co., Ltd. (“CLST”) is to only publish research that is report or to any investment banking relationship with the subject
impartial, independent, clear, fair, and not misleading. Regulations or company covered in this report (for the past one year) or otherwise
market practice of some jurisdictions/markets prescribe certain any other relationship with such company which leads to receipt of
disclosures to be made for certain actual, potential or perceived fees from the company except in ordinary course of business of the
conflicts of interests relating to a research report as below. This company. The analyst/s also state/s and confirm/s that he/she/they
research disclosure should be read in conjunction with the research has/have not been placed under any undue influence, intervention or
disclaimer as set out at www.clsa.com/disclaimer.html and the pressure by any person/s in compiling this research report. In
applicable regulation of the concerned market where the analyst is addition, the analysts included herein attest that they were not in
stationed and hence subject to. Investors are strongly encouraged to possession of any material, nonpublic information regarding the
review this disclaimer before investing. subject company at the time of publication of the report. The analysts
Neither analysts nor their household members/associates/may further confirm that none of the information used in this report was
have a financial interest in, or be an officer, director or advisory board received from CLSA's Corporate Finance department or CLSA's Sales
member of companies covered by the analyst unless disclosed herein. and Trading business. Save from the disclosure below (if any), the
In circumstances where an analyst has a pre-existing holding in any analyst(s) is/are not aware of any material conflict of interest.
securities under coverage, those holdings are grandfathered and the Key to CLSA/CLSA Americas/CLST investment rankings: BUY:
analyst is prohibited from trading such securities. Total stock return (including dividends) expected to exceed 20%; O-
(For full disclosure of interest for all companies mention on this PF (aka ACCUMULATE): Total expected return below 20% but
report, please refer to exceeding market return; U-PF (aka REDUCE): Total expected return
http://www.clsa.com/member/research_disclosures/ for details.) positive but below market return; SELL: Total return expected to be
The analysts included herein hereby confirm that they have not negative. For relative performance, we benchmark the 12-month total
been placed under any undue influence, intervention or pressure by forecast return (including dividends) for the stock against the 12-
any person/s in compiling this research report. In addition, the month forecast return (including dividends) for the market on which
analysts attest that they were not in possession of any material, non- the stock trades.
public information regarding the subject company at the time of "High Conviction" Ideas are not necessarily stocks with the most
publication of the report. Save from the disclosure below (if any), the upside/downside, but those where the Research Head/Strategist
analyst(s) is/are not aware of any material conflict of interest. believes there is the highest likelihood of positive/negative returns.
As analyst(s) of this report, I/we hereby certify that the views The list for each market is monitored weekly.
expressed in this research report accurately reflect my/our own Overall rating distribution for CLSA (exclude CLST) only Universe:
personal views about the securities and/or the issuers and that no Overall rating distribution: BUY / Outperform - CLSA: 77.02%,
part of my/our compensation was, is, or will be directly or indirectly Underperform / SELL - CLSA: 22.98%, Restricted - CLSA: 0.18%; Data
as of 30 Jun 2021. Investment banking clients as a % of rating suitable for your particular circumstances and, if appropriate, seek
category: BUY / Outperform - CLSA: 12.59%, Underperform / SELL - professional advice, including tax advice. Investments involve risks,
CLSA: 1.76%; Restricted - CLSA: 0.18%. Data for 12-month period and investors should exercise prudence and their own judgment in
ending 30 Jun 2021. making their investment decisions. The value of any investment or
Overall rating distribution for CLST only Universe: Overall rating income my go down as well as up, and investors may not get back the
distribution: BUY / Outperform - CLST: 93.44%, Underperform / SELL full (or any) amount invested. Past performance is not necessarily a
- CLST: 6.56%, Restricted - CLST: 0.00%. Data as of 30 Jun 2021. guide to future performance. CLSA, CLSA Americas, and/or CLST
Investment banking clients as a % of rating category: BUY / do/does not accept any responsibility and cannot be held liable for
Outperform - CLST: 0.00%, Underperform / SELL - CLST: 0.00%, any person’s use of or reliance on the information and opinions
Restricted - CLST: 0.00%. Data for 12-month period ending 30 Jun contained herein. To the extent permitted by applicable securities
2021. laws and regulations, CLSA, CLSA Americas, and/or CLST accept(s) no
There are no numbers for Hold/Neutral as CLSA/CLST do not liability whatsoever for any direct or consequential loss arising from
have such investment rankings. For a history of the recommendation, the use of this publication/communication or its contents.
price targets and disclosure information for companies mentioned in To maintain the independence and integrity of our research, our
this report please write to: CLSA Group Compliance, 18/F, One Pacific Corporate Finance, Sales Trading, Asset Management and Research
Place, 88 Queensway, Hong Kong and/or; (c) CLST Compliance (27/F, business lines are distinct from one another. This means that CLSA’s
95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone Research department is not part of and does not report to CLSA
(886) 2 2326 8188). EVA® is a registered trademark of Stern, Stewart Corporate Finance department or CLSA’s Sales and Trading business.
& Co. "CL" in charts and tables stands for CLSA estimates, “CT” stands Accordingly, neither the Corporate Finance nor the Sales and Trading
for CLST estimates, "CRR" stands for CRR Research estimates and department supervises or controls the activities of CLSA’s research
“CS” for Citic Securities estimates unless otherwise noted in the analysts. CLSA’s research analysts report to the management of the
source. Research department, who in turn report to CLSA’s senior
Charts and tables sourced to CLSA in this report may include data management. CLSA has put in place a number of internal controls
extracted from CLSA’s automated databases, which derive their designed to manage conflicts of interest that may arise as a result of
original data from a range of sources. These can include: companies; CLSA engaging in Corporate Finance, Sales and Trading, Asset
analyst estimates/calculations; local exchanges and/or third-party Management and Research activities. Some examples of these
data or market pricing providers such as Bloomberg, FactSet or IBES. controls include: the use of information barriers and other controls
Additional information on data sources for specific charts or tables designed to ensure that confidential information is only shared on a
can be obtained by contacting the publishing analysts. “need to know” basis and in compliance with CLSA’s Chinese Wall
This publication/communication is subject to and incorporates policies and procedures; measures designed to ensure that
the terms and conditions of use set out on the www.clsa.com website interactions that may occur among CLSA’s Research personnel,
(https://www.clsa.com/disclaimer.html). Neither the Corporate Finance, Asset Management, and Sales and Trading
publication/communication nor any portion hereof may be reprinted, personnel, CLSA’s financial product issuers and CLSA’s research
sold, resold, copied, reproduced, distributed, redistributed, published, analysts do not compromise the integrity and independence of CLSA’s
republished, displayed, posted or transmitted in any form or media or research.
by any means without the written consent of CLSA, CLSA Americas Subject to any applicable laws and regulations at any given time,
and/or CLST. CLSA, CLSA Americas and/or CLST has/have produced CLSA, CLSA Americas, CLST, their respective affiliates, officers,
this publication/communication for private circulation to directors or employees may have used the information contained
professional, institutional and/or wholesale clients only, and may not herein before publication and may have positions in, or may from time
be distributed to retail investors. The information, opinions and to time purchase or sell or have a material interest in any of the
estimates herein are not directed at, or intended for distribution to or securities mentioned or related securities, or may currently or in
use by, any person or entity in any jurisdiction where doing so would future have or have had a business or financial relationship with, or
be contrary to law or regulation or which would subject CLSA, CLSA may provide or have provided corporate finance/capital markets
Americas, and/or CLST to any additional registration or licensing and/or other services to, the entities referred to herein, their advisors
requirement within such jurisdiction. The information and statistical and/or any other connected parties. As a result, you should be aware
data herein have been obtained from sources we believe to be that CLSA, CLSA Americas, and/or CLST and/or their respective
reliable. Such information has not been independently verified and we affiliates, officers, directors or employees may have one or more
make no representation or warranty as to its accuracy, completeness conflicts of interest. Regulations or market practice of some
or correctness. Any opinions or estimates herein reflect the judgment jurisdictions/markets prescribe certain disclosures to be made for
of CLSA, CLSA Americas, and/or CLST at the date of this certain actual, potential or perceived conflicts of interests relating to
publication/communication and are subject to change at any time research reports. Details of the disclosable interest can be found in
without notice. Where any part of the information, opinions or certain reports as required by the relevant rules and regulation and
estimates contained herein reflects the views and opinions of a sales the full details are available at
person or a non-analyst, such views and opinions may not correspond http://www.clsa.com/member/research_disclosures/. Disclosures
to the published view of CLSA, CLSA Americas, and/or CLST. Any therein include the position of CLSA, CLSA Americas, and CLST only.
price target given in the report may be projected from one or more Unless specified otherwise, CLSA did not receive any compensation
valuation models and hence any price target may be subject to the or other benefits from the subject company, covered in this
inherent risk of the selected model as well as other external risk publication/communication, or from any third party. If investors have
factors. Where the publication does not contain ratings, the material any difficulty accessing this website, please contact
should not be construed as research but is offered as factual webadmin@clsa.com on +852 2600 8111. If you require disclosure
commentary. It is not intended to, nor should it be used to form an information on previous dates, please contact
investment opinion about the non-rated companies. compliance_hk@clsa.com.
This publication/communication is for information purposes only This publication/communication is distributed for and on behalf
and it does not constitute or contain, and should not be considered as of CLSA (for research compiled by non-US and non-Taiwan analyst(s)),
an offer or invitation to sell, or any solicitation or invitation of any CLSA Americas, and/or CLST (for research compiled by Taiwan
offer to subscribe for or purchase any securities in any jurisdiction analyst(s)) in Australia by CLSA Australia Pty Ltd (ABN 53 139 992
and recipient of this publication/communication must make its own 331/AFSL License No: 350159); in Hong Kong by CLSA Limited
independent decisions regarding any securities or financial (Incorporated in Hong Kong with limited liability); in India by CLSA
instruments mentioned herein. This is not intended to provide India Private Limited, (Address: 8/F, Dalamal House, Nariman Point,
professional, investment or any other type of advice or Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-
recommendation and does not take into account the particular 22840271; CIN: U67120MH1994PLC083118; SEBI Registration No:
investment objectives, financial situation or needs of individual INZ000001735 as Stock Broker, INM000010619 as Merchant Banker
recipients. Before acting on any information in this and INH000001113 as Research Analyst,; in Indonesia by PT CLSA
publication/communication, you should consider whether it is Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd.; in
Korea by CLSA Securities Korea Ltd.; in Malaysia by CLSA Securities Financial Advisers Regulations and the relevant Notices and
Malaysia Sdn. Bhd.; in the Philippines by CLSA Philippines Inc (a Guidelines issued thereunder (as disclosed in Part C of the Securities
member of Philippine Stock Exchange and Securities Investors Dealing Services – Singapore Annex of the CLSA terms of business),
Protection Fund); in Singapore by CLSA Singapore Pte Ltd and solely in respect of any financial advisory services that CLSA Singapore Pte
to persons who qualify as an "Institutional Investor", "Accredited Ltd may provide to you. MCI (P) 024/12/2020
Investor" or "Expert Investor" MCI (P) 024/12/2020; in Thailand by United States of America: Where any section of the research is
CLSA Securities (Thailand) Limited; in Taiwan by CLST and in the EU compiled by US analyst(s), it is distributed by CLSA Americas. Where
and United Kingdom by CLSA Europe BV or CLSA (UK). any section is compiled by non-US analyst(s), it is distributed into the
Australia: CLSA Australia Pty Ltd (“CAPL”) (ABN 53 139 992 United States by CLSA solely to persons who qualify as "Major US
331/AFS License No: 350159) is regulated by ASIC and is a Market Institutional Investors" as defined in Rule 15a-6 under the Securities
Participant of ASX Limited and CHI-X. This material is issued and and Exchange Act of 1934 and who deal with CLSA Americas.
distributed by CAPL in Australia to "wholesale clients" only. This However, the delivery of this research report to any person in the
material does not take into account the specific investment United States shall not be deemed a recommendation to effect any
objectives, financial situation or particular needs of the recipient. The transactions in the securities discussed herein or an endorsement of
recipient of this material must not distribute it to any third party any opinion expressed herein. Any recipient of this research in the
without the prior written consent of CAPL. For the purposes of this United States wishing to effect a transaction in any security
paragraph the term "wholesale client" has the meaning given in mentioned herein should do so by contacting CLSA Americas.
section 761G of the Corporations Act 2001. CAPL’s research The European Union (“EU”) and the United Kingdom: In these
coverage universe spans listed securities across the ASX All jurisdictions, this research is a marketing communication. It has not
Ordinaries index, securities listed on offshore markets, unlisted been prepared in accordance with the legal requirements designed to
issuers and investment products which Research management deem promote the independence of investment research, and is not subject
to be relevant to the investor base from time to time. CAPL seeks to to any prohibition on dealing ahead of the dissemination of
cover companies of relevance to its domestic and international investment research. The research is disseminated in these countries
investor base across a variety of sectors. by either CLSA (UK) or CLSA Europe BV. CLSA (UK) is authorised and
India: CLSA India Private Limited, incorporated in November 1994 regulated by the Financial Conduct Authority. CLSA Europe BV is
provides equity brokerage services (SEBI Registration No: authorised and regulated by the Authority for Financial Markets in the
INZ000001735), research services (SEBI Registration No: Netherlands. This document is directed at persons having
INH000001113) and merchant banking services (SEBI Registration professional experience in matters relating to investments as defined
No.INM000010619) to global institutional investors, pension funds in the relevant applicable local regulations. Any investment activity to
and corporates. CLSA and its associates may have debt holdings in the which it relates is only available to such persons. If you do not have
subject company. Further, CLSA and its associates, in the past 12 professional experience in matters relating to investments you should
months, may have received compensation for non-investment not rely on this document. Where the research material is compiled
banking securities and/or non-securities related services from the by the UK analyst(s), it is produced and disseminated by CLSA (UK)
subject company. For further details of “associates” of CLSA India and CLSA Europe BV. For the purposes of the Financial Conduct Rules
please contact Compliance-India@clsa.com. in the United Kingdom and MIFID II in other European jurisdictions
Singapore: This report is distributed in Singapore by CLSA this research is prepared and intended as substantive research
Singapore Pte Ltd to institutional investors, accredited investors or material.
expert investors (each as defined under the Financial Advisers For all other jurisdiction-specific disclaimers please refer to
Regulations) only. Singapore recipients should contact CLSA https://www.clsa.com/disclaimer.html. The analysts/contributors to
Singapore Pte Ltd, 80 Raffles Place, #18-01, UOB Plaza 1, Singapore this publication/communication may be employed by any relevant
048624, Tel: +65 6416 7888, in respect of any matters arising from, CLSA entity or CLST, which is different from the entity that
or in connection with, the analysis or report. By virtue of your status distributes the publication/communication in the respective
as an institutional investor, accredited investor or expert investor, jurisdictions.© 2021 CLSA and/or CL Securities Taiwan Co., Ltd.
CLSA Singapore Pte Ltd is exempted from complying with certain (“CLST”).
requirements under the Financial Advisers Act (Chapter 110), the